35 results about "Dihydroorotate Dehydrogenase Inhibitor" patented technology

The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1) inhibitor, a cyclooxygenase inhibitor, an α2δ voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) as follows: 5 wherein R1, R2, R3, R4, R5a, R5b, X and Y, are defined herein.

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows:wherein R1, R2, R3, R4, X, and Y are defined herein.

The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and / or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.

Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.

Methods for assessing the efficacy of dihydroorotate dehydrogenase inhibitors in the treatment of cancer and methods of using such inhibitors to treat PTEN-mutant cancer are provided.

Disclosed are compounds, compositions, and methods for treating diseases, disorders, or medical conditions affected by DHODH modulation. Such compounds are represented by the following Formula I: wherein R1, R2, R3 and R6 are as defined herein.

Methods for assessing the efficacy of dihydroorotate dehydrogenase inhibitors in the treatment of cancer and methods of using such inhibitors to treat PTEN-mutant cancer are provided.

Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound:and a triazolopyrimidine class of compounds that conform to Formula IX:and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.

The present invention provides a combination comprising (a) methotrexate and (b) a non-hepatotoxic dihydroorotate dehydrogenase (DHODH) inhibitor of formula (I): wherein: R1 consists of a hydrogen atom, a halogen atom, C1-4 alkyl, C3-4 cycloalkyl, -CF3 and -OCF3; R2 is selected from the group consisting of hydrogen atom, halogen atom and C1-4 alkyl; R3 Selected from the group consisting of -COOR5, -CONHR5, tetrazolyl, -SO2NHR5 and -CONHSO2R5 groups, wherein R5 is selected from the group consisting of hydrogen atoms and straight-chain or branched C1-4 alkyl groups; R4 is selected from the group consisting of a hydrogen atom and a C1-4 alkyl group; R9 is selected from a group consisting of a hydrogen atom and a phenyl group; G1 represents a group selected from N and CR6, wherein R6 is composed of a hydrogen atom, Halogen atom, C1-4 alkyl, C3-4 cycloalkyl, C1-4 alkoxy, -CF3, -OCF3, N-containing monocyclic C5-7 heteroaryl, N-containing monocyclic C3-7 heterocyclic And selected from the group consisting of C6-10 aryl groups, said C6-10 aryl groups may be optionally substituted by one or more substituents selected from halogen atoms and C1-4 alkyl groups; G2 means selected from the following Groups in the group: hydrogen atom, hydroxyl, halogen atom, C3-4 cycloalkyl, C1-4 alkoxy and -NRaRb, wherein Ra represents C1-4 alkyl and Rb consists of C1-4 alkyl and C1 - selected from the group consisting of 4 alkoxy-C1-4 alkyl, or Ra and Rb together with the nitrogen atom to which they are attached form a saturated 6 to 8 which may optionally contain an oxygen atom as another heteroatom membered heterocyclic ring; monocyclic or bicyclic 5 to 10 membered heteroaryl ring containing one or more nitrogen atoms, which may be optionally replaced by one or more members selected from halogen atoms, C1-4 alkyl, C1-4 alkoxy Substituents of radical, C3-4 cycloalkyl, C3-4 cycloalkoxy, -CF3, -OCF3 and -CONR7R8, wherein R7 and R8 are independently selected from hydrogen atom, straight chain or branched chain C1-4 alkane group, C3-7 cycloalkyl group, or R7 and R8, together with the nitrogen atom to which they are attached, form a group of the following formula: wherein n is an integer from 0 to 3; and phenyl, which may optionally be replaced by one or more One selected from halogen atom, C1-4 alkyl, hydroxyl, C1-4 alkoxy, C3-4 cycloalkyl, C3-4 cycloalkoxy, cyano, -CF3, -OCF3, -CONR7R8, oxadiazole Substituents of diazolyl, triazolyl, pyrazolyl and imidazolyl, said diazolyl, triazolyl, pyrazolyl and imidazolyl can be optionally replaced by C1-4 alkyl or C3-7 cycloalkyl Substituted and wherein R7 and R8 are independently selected from a hydrogen atom, a straight or branched C1-4 alkyl group, a C3-7 cycloalkyl group, or R7 and R8 together with the nitrogen atom to which they are attached form a group of the following formula: wherein n is an integer from 0 to 3; or, when G' represents CR6, G2 together with R6 forms a non-aromatic C5-10 carbocyclic group or a C6-10 aryl group, and its pharmaceutical Pharmaceutically acceptable salts and N oxides.

The invention provides a bisporin compound and its application in the preparation of antitumor drugs or dihydroorotate dehydrogenase inhibitor drugs, and relates to the field of marine natural products. An ascochlorin compound is disclosed, the structural formula of which is shown in formula (I). The cyclohexanol fragment of the compound has a rare gem-dimethyl group and an extracyclic double bond, and has a broad spectrum of significant tumor cell Proliferation inhibitory activity and dihydroorotate dehydrogenase inhibitory activity, so it is an ideal candidate compound to be developed as an anti-tumor drug or a dihydroorotate dehydrogenase inhibitor drug with novel structure and high activity.

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows:wherein R1a, R1b, R2, and R3, are defined herein.

The invention provides a novel dihydroorotate dehydrogenase inhibitor, which can be applied to various diseases. The active ingredients include formula (I) (in the formula, X represents a halogen atom, R1 represents a hydrogen atom, R2 represents an alkyl group with 1 to 7 carbons, R3 represents -CHO, R4 represents -CH2-CH=C(CH3) A compound represented by -R0 (where R0 represents an alkyl group with 1 to 12 carbons that may have substituents on the terminal carbon and / or non-terminal carbon, etc.)), its optical isomers, and the compounds and The pharmaceutically acceptable salt of the optical isomer has a good inhibitory effect on dihydroorotate dehydrogenase, and can be used as an immunosuppressant, rheumatoid therapeutic agent, anticancer agent, rejection treatment drug, and antiviral drug , anti-H.pylori (Helicobacter pylori) drugs and diabetes treatment drugs, etc.

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) as follows:wherein R1, R2, R3, R4, R5a, R5b, X and Y, are defined herein.

Compounds according to Formula I, Formula II, Formula III, Formula V, Formula VI, or to Formula VII,and pharmaceutical compositions of compounds that conform to Formula IV or Formula VIII:where R1 through R33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.

Inhibitors of dihydroorotate dehydrogenase (DHODH) for the Plasmodium enzyme have been identified and characterized. The inhibitors have high specificity, submicromolar efficacy against cultured parasite strains, exhibit drug-like properties, and are not overtly cytotoxic.

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.